Analyst resumed coverage on Treace Medical Concepts with a new price target
$TMCI
Medical/Dental Instruments
Health Care
Analyst resumed coverage of Treace Medical Concepts with a rating of Neutral and set a new price target of $8.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/7/2025 | $5.00 | Neutral → Underweight | Analyst |
| 11/7/2025 | Buy → Neutral | BTIG Research | |
| 2/4/2025 | $16.00 | Neutral → Buy | BTIG Research |
| 12/31/2024 | $14.50 | Buy | Lake Street |
| 12/17/2024 | $8.00 | Neutral | Analyst |
| 5/16/2024 | $16.00 → $6.50 | Buy → Neutral | UBS |
| 5/8/2024 | $15.00 → $5.50 | Overweight → Equal-Weight | Morgan Stanley |
| 5/8/2024 | $17.00 → $7.00 | Buy → Hold | Truist |
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
Analyst downgraded Treace Medical Concepts from Neutral to Underweight and set a new price target of $5.00
BTIG Research downgraded Treace Medical Concepts from Buy to Neutral
BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00
PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period in 2024.Preliminary revenue of $212.3 million to $212.7 million for the full-year 2025, an approximate 2% increase at the midpoint compared to the prior year and in-line with the previousl
PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty® Lightning™ technology. Lightning technology expands upon Treace's market-leading Lapiplasty® System with advanced new instrumentation designed to reduce surgical steps, precisely correct in all three planes, and further streamline procedural workflow with Treace's SpeedPlate® Rapid Compression Fixation technology. "As the pioneers and leaders in instrumen
PONTE VEDRA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that John T. Treace, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, beginning at approximately 7:30 am PT. A live webcast and replay of the fireside chat will be available on the Company's investors relations website at https://investors.treace.com/. Internet Posting of InformationTreace routinely posts information that may be important to investors
PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B
PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts. "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou
PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit
PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results. Highlights: Preliminary revenue of $62.1 million to $62.5 million in the fourth quarter of 2025, an approximate 9% decrease at the midpoint over the same period in 2024.Preliminary revenue of $212.3 million to $212.7 million for the full-year 2025, an approximate 2% increase at the midpoint compared to the prior year and in-line with the previousl
PONTE VEDRA, Fla., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Generated revenue of $50.2 million in third quarter 2025 representing growth of 11% over the same period in 2024. Reported third quarter 2025 net loss of $(16.3) million and improved adjusted EBITDA by 49% to $(2.6) million in the third quarter 2025 compared to $(5.1) million in the same period in 2024.Presented clinical data at the American
PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live a
SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)